Ligand Pharmaceuticals (LGND) Assets (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Assets of $1.5 billion in Q1 2026, down 1.83% quarter-over-quarter from $1.6 billion in Q4 2025, and up 69.21% year-over-year from $905.4 million in Q1 2025.
Ligand Pharmaceuticals' Assets history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Assets rose 69.21% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 69.21% YoY), while the FY2025 annual figure was $1.6 billion, up 65.71% from the prior year.
- Assets came in at $1.5 billion for Q1 2026 at Ligand Pharmaceuticals, down from $1.6 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $1.6 billion in Q4 2025 to a low of $758.1 million in Q2 2023.
- A 5-year average of $1.0 billion and a median of $941.8 million in 2024 frame the typical range for Assets.
- Across the five-year window, Assets sank 41.22% in 2022 and soared 69.21% in 2026, its largest moves.
- Ligand Pharmaceuticals' Assets stood at $762.7 million in 2022, then advanced by 3.22% to $787.2 million in 2023, then climbed by 19.63% to $941.8 million in 2024, then soared by 65.71% to $1.6 billion in 2025, then dropped by 1.83% to $1.5 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | 1.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.56 Bn |
| Sep 30, 2025 | 1.48 Bn |
| Jun 30, 2025 | 948.60 Mn |
| Mar 31, 2025 | 905.44 Mn |
| Dec 31, 2024 | 941.77 Mn |
| Sep 30, 2024 | 954.87 Mn |
| Jun 30, 2024 | 866.41 Mn |
| Mar 31, 2024 | 913.87 Mn |
| Dec 31, 2023 | 787.22 Mn |
| Sep 30, 2023 | 769.23 Mn |
| Jun 30, 2023 | 758.11 Mn |
| Mar 31, 2023 | 811.08 Mn |
| Dec 31, 2022 | 762.67 Mn |
| Sep 30, 2022 | 1.05 Bn |
| Jun 30, 2022 | 1.08 Bn |
| Mar 31, 2022 | 1.11 Bn |
| Dec 31, 2021 | 1.30 Bn |
| Sep 30, 2021 | 1.27 Bn |
| Jun 30, 2021 | 1.26 Bn |
| Mar 31, 2021 | 1.30 Bn |
| Dec 31, 2020 | 1.36 Bn |
| Sep 30, 2020 | 1.25 Bn |
| Jun 30, 2020 | 1.24 Bn |
| Mar 31, 2020 | 1.19 Bn |
| Dec 31, 2019 | 1.49 Bn |
| Sep 30, 2019 | 1.55 Bn |
| Jun 30, 2019 | 1.80 Bn |
| Mar 31, 2019 | 1.91 Bn |
| Dec 31, 2018 | 1.26 Bn |
| Sep 30, 2018 | 2.11 Bn |
| Jun 30, 2018 | 1.86 Bn |
| Mar 31, 2018 | 754.67 Mn |
| Dec 31, 2017 | 671.02 Mn |
| Sep 30, 2017 | 662.34 Mn |
| Jun 30, 2017 | 640.02 Mn |
| Mar 31, 2017 | 629.72 Mn |
| Dec 31, 2016 | 601.59 Mn |
| Jun 30, 2016 | 616.80 Mn |
| Mar 31, 2016 | 613.44 Mn |
| Dec 31, 2015 | 503.06 Mn |
| Sep 30, 2015 | 521.70 Mn |
| Jun 30, 2015 | 304.76 Mn |
| Mar 31, 2015 | 263.22 Mn |
| Dec 31, 2014 | 258.03 Mn |
| Sep 30, 2014 | 272.28 Mn |
| Jun 30, 2014 | 99.85 Mn |
| Mar 31, 2014 | 105.47 Mn |
| Dec 31, 2013 | 104.71 Mn |
| Sep 30, 2013 | 101.68 Mn |
| Jun 30, 2013 | 99.57 Mn |
| Mar 31, 2013 | 98.36 Mn |
| Dec 31, 2012 | 104.26 Mn |
| Sep 30, 2012 | 97.51 Mn |
| Mar 31, 2012 | 111.80 Mn |
| Dec 31, 2011 | 120.58 Mn |
| Sep 30, 2011 | 123.16 Mn |
| Jun 30, 2011 | 127.98 Mn |
| Dec 31, 2010 | 75.56 Mn |